Franklin R Schneier1, Mark Slifstein2, Alexis E Whitton3, Diego A Pizzagalli3, Jenna Reinen4, Patrick J McGrath5, Dan V Iosifescu6, Anissa Abi-Dargham2. 1. Division of Clinical Therapeutics, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York; Department of Psychiatry, Columbia University Medical Center, New York, New York. Electronic address: fschneier@nyspi.columbia.edu. 2. Division of Translational Imaging, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York; Department of Psychiatry, Columbia University Medical Center, New York, New York. 3. Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont; Department of Psychiatry, Harvard Medical School, Cambridge, Massachusetts. 4. Department of Psychology, Columbia University Medical Center, New York, New York; Department of Psychology, Yale University, New Haven, Connecticut. 5. Division of Clinical Therapeutics, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York; Department of Psychiatry, Columbia University Medical Center, New York, New York. 6. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: Mesolimbic dopamine system dysfunction is believed to contribute to major depressive disorder (MDD), but molecular neuroimaging of striatal dopamine neurotransmission has yielded mixed results, possibly owing to limited sensitivity of antagonist radioligands used with positron emission tomography to assess dopamine release capacity. This study used an agonist radioligand with agonist challenge to assess dopamine release capacity and D2/D3 receptor availability in MDD. METHODS: Twenty-six treatment-naive adults with MDD and 26 healthy comparison participants underwent functional magnetic resonance imaging during a probabilistic reinforcement task, and positron emission tomography with the D3-preferring ligand [11C]-(+)-PHNO, before and after oral dextroamphetamine. MDD participants then received pramipexole treatment for 6 weeks. RESULTS: MDD participants had trend-level greater dopamine release capacity in the ventral striatum, as measured by percent change in baseline binding potential relative to nondisplaceable compartment (ΔBPND) (-34% vs. -30%; p = .072, d = 0.58) but no difference in D2/D3 receptor availability (BPND). Striatal and extrastriatal BPND and percent change in baseline BPND were not significantly associated with blood oxygen level-dependent response to reward prediction error in the ventral striatum, severity of depression and anhedonia, or antidepressant response to pramipexole (response rate = 72.7%). CONCLUSIONS: [11C]-(+)-PHNO demonstrated high sensitivity to displacement by amphetamine-induced dopamine release, but dopamine release capacity and D2/D3 availability were not associated with ventral striatal activation to reward prediction error or clinical features, in this study powered to detect large effects. While a preponderance of indirect evidence implicates dopaminergic dysfunction in MDD, these findings suggest that presynaptic dopamine dysregulation may not be a feature of MDD or a prerequisite for treatment response to dopamine agonists.
BACKGROUND:Mesolimbicdopaminesystem dysfunction is believed to contribute to major depressive disorder (MDD), but molecular neuroimaging of striatal dopamine neurotransmission has yielded mixed results, possibly owing to limited sensitivity of antagonist radioligands used with positron emission tomography to assess dopamine release capacity. This study used an agonist radioligand with agonist challenge to assess dopamine release capacity and D2/D3 receptor availability in MDD. METHODS: Twenty-six treatment-naive adults with MDD and 26 healthy comparison participants underwent functional magnetic resonance imaging during a probabilistic reinforcement task, and positron emission tomography with the D3-preferring ligand [11C]-(+)-PHNO, before and after oral dextroamphetamine. MDDparticipants then received pramipexole treatment for 6 weeks. RESULTS:MDDparticipants had trend-level greater dopamine release capacity in the ventral striatum, as measured by percent change in baseline binding potential relative to nondisplaceable compartment (ΔBPND) (-34% vs. -30%; p = .072, d = 0.58) but no difference in D2/D3 receptor availability (BPND). Striatal and extrastriatal BPND and percent change in baseline BPND were not significantly associated with blood oxygen level-dependent response to reward prediction error in the ventral striatum, severity of depression and anhedonia, or antidepressant response to pramipexole (response rate = 72.7%). CONCLUSIONS:[11C]-(+)-PHNO demonstrated high sensitivity to displacement by amphetamine-induced dopamine release, but dopamine release capacity and D2/D3 availability were not associated with ventral striatal activation to reward prediction error or clinical features, in this study powered to detect large effects. While a preponderance of indirect evidence implicates dopaminergic dysfunction in MDD, these findings suggest that presynaptic dopamine dysregulation may not be a feature of MDD or a prerequisite for treatment response to dopamine agonists.
Authors: Jenna Reinen; Edward E Smith; Catherine Insel; Robert Kribs; Daphna Shohamy; Tor D Wager; L Fredrik Jarskog Journal: Schizophr Res Date: 2013-12-13 Impact factor: 4.939
Authors: R V Parsey; M A Oquendo; Y Zea-Ponce; J Rodenhiser; L S Kegeles; M Pratap; T B Cooper; R Van Heertum; J J Mann; M Laruelle Journal: Biol Psychiatry Date: 2001-09-01 Impact factor: 13.382
Authors: Andri C Tziortzi; Graham E Searle; Sofia Tzimopoulou; Cristian Salinas; John D Beaver; Mark Jenkinson; Marc Laruelle; Eugenii A Rabiner; Roger N Gunn Journal: Neuroimage Date: 2010-06-30 Impact factor: 6.556
Authors: Jenna M Reinen; Alexis E Whitton; Diego A Pizzagalli; Mark Slifstein; Anissa Abi-Dargham; Patrick J McGrath; Dan V Iosifescu; Franklin R Schneier Journal: Eur Neuropsychopharmacol Date: 2021-09-10 Impact factor: 4.600
Authors: Ragy R Girgis; Mark Slifstein; Gary Brucato; Lawrence S Kegeles; Tiziano Colibazzi; Jeffrey A Lieberman; Anissa Abi-Dargham Journal: Mol Psychiatry Date: 2020-11-05 Impact factor: 13.437
Authors: Alexis E Whitton; Jenna M Reinen; Mark Slifstein; Yuen-Siang Ang; Patrick J McGrath; Dan V Iosifescu; Anissa Abi-Dargham; Diego A Pizzagalli; Franklin R Schneier Journal: Brain Date: 2020-02-01 Impact factor: 13.501
Authors: Paul Cernasov; Erin C Walsh; Jessica L Kinard; Lisalynn Kelley; Rachel Phillips; Angela Pisoni; Tory A Eisenlohr-Moul; Macey Arnold; Sarah C Lowery; Marcy Ammirato; Kinh Truong; Gabriela A Nagy; Jason A Oliver; Kevin Haworth; Moria Smoski; Gabriel S Dichter Journal: J Affect Disord Date: 2021-05-28 Impact factor: 6.533
Authors: Warren D Taylor; David H Zald; Jennifer C Felger; Seth Christman; Daniel O Claassen; Guillermo Horga; Jeffrey M Miller; Katherine Gifford; Baxter Rogers; Sarah M Szymkowicz; Bret R Rutherford Journal: Mol Psychiatry Date: 2021-08-17 Impact factor: 15.992